Category: Psychedelic Bulletin - Page 10 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

Post published:September 12, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics

Psychedelic Bulletin #117 – A Deep Dive Into Psilocybin for Alcohol Use Disorder; Former MindMed CMO Alleges IP Was Syphoned off to Competitor; ARK Discusses Psychedelics

Post published:September 6, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops Plan to Schedule 2 Psychedelics, for Now; Analysis of Oregon Psilocybin Opt-Outs

Post published:August 29, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains ‘Meme Stock’ Status; atai ‘Streamlilnes’ Pipeline; California Decrim. Bill Gutted

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains ‘Meme Stock’ Status; atai ‘Streamlilnes’ Pipeline; California Decrim. Bill Gutted

Post published:August 19, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle

Psychedelic Bulletin #114 – Lawsuit Alleges Compass Stole Trade Secrets; MindMed CMO Turns Activist Shareholder; California Decrim. Bill Tentatively Clears Hurdle

Post published:August 12, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies

Psychedelic Bulletin #113 – Analysis of Company Spending Trends; Morgan Stanley Opine on Psychedelics; COMPASS Rallies

Post published:August 6, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing

Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company Enters Death Spiral Financing

Post published:July 29, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms?

Psychedelic Bulletin #111 – Psychedelics on Netflix; House Adopts 2 Psychedelic Research Amendments; Taking the Magic Out of Magic Mushrooms?

Post published:July 15, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics

Post published:July 11, 2022
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails?

Post published:July 4, 2022
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.